Imunon (IMNN) Stock Price, News & Analysis

Company Overview

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Key Stats

• Today's Range: $1.51 to $1.59
• 50-Day Range: $1.51 to $2.06
• 52-Week Range: $1.47 to $6.03
• Volume: 7,368 shs
• Average Volume: 91,736 shs
• Market Capitalization: $8.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

Imunon Stock Analysis - MarketRank™

Imunon scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Imunon has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Imunon has a consensus price target of $10.00, representing about 534.9% upside from its current price of $1.58.

Amount of Analyst Coverage

Imunon has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Imunon are expected to grow in the coming year, from ($2.37) to ($2.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Imunon is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Imunon is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Imunon has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.07% of the float of Imunon has been sold short.

Short Interest Ratio / Days to Cover

Imunon has a short interest ratio ("days to cover") of 2.53, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Imunon has recently decreased by 24.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Imunon does not currently pay a dividend.

Dividend Growth

Imunon does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.

MarketBeat Follows

4 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Imunon insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,188.00 in company stock.

Percentage Held by Insiders

2.83% of the stock of Imunon is held by insiders.

Percentage Held by Institutions

4.47% of the stock of Imunon is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/03/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMNN
• CIK: 749647
• Web: www.imunon.com
• Phone: (609) 896-9100
• Fax: 609-896-2200
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Imunon: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +527.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -358.01%
• Return on Assets: -132.91%

Debt

• Debt-to-Equity Ratio: 2.86
• Current Ratio: 1.82
• Quick Ratio: 1.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 4.55

Miscellaneous

• Outstanding Shares: 5,611,000
• Free Float: 5,452,000
• Market Cap: $8.94 million
• Optionable: Not Optionable
• Beta: 1.98